VYGR
Voyager Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.51
+3.85%Year over year
Reported trailing growth
- Revenue
- -19.1%
- EBITDA
- +8.3%
- EBIT
- +5.0%
- EPS
- +2.2%
- Free cash flow
- -4.8%
- Operating cash flow
- -6.1%
Forward estimates
Based on analyst estimates
- Revenue
- -26.7%
- EBITDA
- +14.0%
- EPS
- +13.2%
Three-year CAGR
- Revenue
- -0.4%
- EBITDA
- -93.8%
- EBIT
- -58.3%
- Net income
- -84.2%
- EPS
- -80.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026